General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.16 | N/A | N/A | N/A |
2024-03-14 | 2023-12 | -0.15 | -0.12 | 0.03 | 20.00% |
2023-11-02 | 2023-09 | -0.18 | -0.11 | 0.07 | 38.89% |
2023-08-03 | 2023-06 | -0.19 | -0.16 | 0.03 | 15.79% |
2023-05-04 | 2023-03 | -0.19 | -0.19 | N/A | N/A |
2023-03-15 | 2022-12 | -0.22 | -0.18 | 0.04 | 18.18% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-12-18 | B. Riley Securities | Upgrade | Neutral | |
2022-09-01 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-05-18 | B. Riley Securities | Upgrade | Neutral | |
2021-11-01 | Cantor Fitzgerald | Upgrade | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | BERG EDWARD B | General Counsel | 270.71K | Stock Award(Grant) |
2024-03-17 | CUMMINGS JAMES F. | Officer | 330.09K | Stock Award(Grant) |
2023-06-25 | FINNEY MICHAEL J | Director | 670.84K | Stock Award(Grant) |
2023-06-25 | HERON ELAINE J | Director | 24.57K | Stock Award(Grant) |
2024-03-17 | LEE PHILLIP E. | Chief Financial Officer | 241.81K | Stock Award(Grant) |
2024-03-17 | LO STEVEN | Chief Executive Officer | 250.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cantor Fitzgerald, L. P. | 7.09M | 5.17M | 4.66% |
2023-06-29 | Vanguard Group Inc | 6.89M | 5.03M | 4.54% |
2023-06-29 | Millennium Management Llc | 2.14M | 1.56M | 1.41% |
2023-06-29 | Blackrock Inc. | 1.93M | 1.41M | 1.27% |
2023-06-29 | Geode Capital Management, LLC | 1.57M | 1.15M | 1.03% |
2023-06-29 | Renaissance Technologies, LLC | 792.01K | 578.16K | 0.52% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.07M | 2.97M | 2.68% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.77M | 1.29M | 1.16% |
2023-05-30 | Fidelity Extended Market Index Fund | 631.59K | 770.54K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 559.90K | 683.08K | 0.37% |
2023-05-30 | Vanguard Health Care Index Fund | 480.63K | 586.37K | 0.32% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 361.97K | 264.24K | 0.24% |
Dividend | Date |
---|---|
0.1847 | 2012-11-09 |
Split | Date |
---|---|
1 : 11 | 2018-02-14 |
0.16667 : 1 | 2012-11-09 |
VXRT Looks like it wants to bounce off the 200 MA AT AROUND .86 and then move to the next leg up.
$VXRT Just saying if my crypto plays are moving I might move this money to crypto for a bit then bring it back.
Tomorrow earnings report $$ coming
$VXRT I saw the same trading action w MAXWELL just before Tesla bought them.
$VXRT I got $500 on it. Let’s see what happens
$VXRT $4 target by mid July. Seems to be ascending in a pretty symmetrical cup formation.
Visionary Education Technology: Registration statement for securities of certain Canadian issuers (Amendment)
SEC announcement
·
03/25/2022 08:22
Visionary Education Technology(VEDU.US)
0.194
+16.03%
This announcement includes 6 separate documents:
Doc 1: View Original
Doc 2: View Original
Doc 3: View Original
Doc 4: View Original
Doc 5: View Original
Doc 6: View Original
This presentation is for informationa
All u need is a good news and should be at 5$ level
$VXRT over $1 then CEO does an offering what an idiot and I thought nothing could be worse than $MULN. Boy I was wrong again…..Fire the CEO!
$VXRT Money money money : What the old crocs of drug industry won’t like:
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
Vaxart is winning in two crucial areas.
Adria Cimino
Vaxart ( VXRT 8.68% ) surged early in the coronavirus vaccine race. It climbed 2,400% in the first six months of 2020. That's as investors bet it would bring a potentially game-changing candidate to market. But Vaxart's program didn't move as quickly as those of vaccine market leaders Pfizer and Moderna. Vaxart's candidate currently is in a phase 2 study.
Data is expected in the first half of this year. But Vaxart has released reports from some preclinical studies that offer us reason to be optimistic. In fact, 19 words from Vaxart's chief scientific officer may mean big things for the biotech -- and trouble for vaccine rivals.
An investor studies something on a laptop and takes notes in a living room setting.
Image source: Getty Images.
Targeting where infection begins
CSO Sean Tucker's words relate to a non-human primate study involving the vaccine candidate. So first, a bit of information on that study. Vaxart is testing an oral vaccine candidate. It's taken in tablet form. The company said this candidate produced antibody levels in blood serum similar to those of injectable vaccines. But it also produced antibody responses in mucosal sites -- such as the nose. This is key because this is where infection actually begins.
Now here are the words that could make things difficult for rivals:
"These antibodies are only minimally induced in currently authorized vaccines and may be key to protecting against new variants," Tucker said.
Why could antibodies in the mucosa better handle variants? Tucker uses omicron as an example. This variant mainly replicates in the upper respiratory tract. And that means antibodies on site might be more effective than those in the blood.
Tucker also said mucosal response could reduce transmission of the virus. This has been another challenge for vaccine makers. Today's vaccines haven't absolutely proved the ability to cut transmission of the virus from person to person.
Today's Change
file:///var/mobile/Library/SMS/Attachments/be/14/D3630F80-4A1E-455C-9321-A26900F1B4F8/original.pdf
Need vaccines. Big recession coming!!!!🥲🥲🥲🥲🥲
Very patient. Been holding #51,000 since March 2020. Don’t mind holding longer. But….thoroughly disgusted by Vaxart’s public proclamations and then not following thru.
Is there a link to the presentation?